Dr. Waldemer Carlo, M.D.
Claim this profileMore about Waldemer Carlo, M.D.
Clinical Trial Related
4 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical Trials
Treatments Waldemer Carlo, M.D. has experience with
- Autologous Mononuclear Cells
Breakdown of trials Waldemer Carlo, M.D. has run
Hypoplastic Left Heart Syndrome
Congenital Heart Diseases
Tetralogy of Fallot
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Waldemer Carlo, M.D. specialize in?
Waldemer Carlo, M.D. focuses on Hypoplastic Left Heart Syndrome and Congenital Heart Diseases. In particular, much of their work with Hypoplastic Left Heart Syndrome has involved treating patients, or patients who are undergoing treatment.
Is Waldemer Carlo, M.D. currently recruiting for clinical trials?
No, Waldemer Carlo, M.D. is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that Waldemer Carlo, M.D. has studied deeply?
Yes, Waldemer Carlo, M.D. has studied treatments such as Autologous Mononuclear Cells.
What is the best way to schedule an appointment with Waldemer Carlo, M.D.?
Apply for one of the trials that Waldemer Carlo, M.D. is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.